ELDN
Income statement / Annual
Last year (2024), Eledon Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Eledon Pharmaceuticals, Inc.'s net income was -$36.18 M.
See Eledon Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$359.00 K
|
$374.00 K
|
$373.00 K
|
$195.00 K
|
$183.00 K
|
$182.00 K
|
$11.00 K
|
$22.00 K
|
$35.00 K
|
$109.00 K
|
| Gross Profit |
-$359.00 K
|
-$374.00 K
|
-$373.00 K
|
-$195.00 K
|
-$183.00 K
|
-$182.00 K
|
-$11.00 K
|
-$22.00 K
|
-$35.00 K
|
-$109.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$51.96 M
|
$30.31 M
|
$27.08 M
|
$23.74 M
|
$6.13 M
|
$8.13 M
|
$6.82 M
|
$2.02 M
|
$25.02 M
|
$32.64 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.24 M
|
$11.10 M
|
$13.10 M
|
$12.62 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.25 M
|
$12.31 M
|
$12.33 M
|
$12.94 M
|
$6.97 M
|
$5.87 M
|
$7.24 M
|
$11.10 M
|
$13.10 M
|
$12.62 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$5.00 K
|
$5.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$70.22 M
|
$42.63 M
|
$39.41 M
|
$36.67 M
|
$13.10 M
|
$14.00 M
|
$14.06 M
|
$13.12 M
|
$38.12 M
|
$45.26 M
|
| Cost And Expenses |
$70.58 M
|
$43.00 M
|
$39.78 M
|
$36.87 M
|
$13.28 M
|
$14.18 M
|
$14.06 M
|
$13.12 M
|
$38.12 M
|
$45.26 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$174.00 K
|
| Depreciation & Amortization |
$359.00 K
|
$374.00 K
|
$373.00 K
|
$195.00 K
|
$183.00 K
|
$182.00 K
|
$11.00 K
|
$22.00 K
|
$35.00 K
|
$109.00 K
|
| EBITDA |
-$35.39 M |
-$116.16 M |
-$87.59 M |
-$36.67 M |
-$23.03 M |
-$15.83 M |
-$14.05 M |
-$13.10 M |
-$6.90 M |
-$44.98 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$34.82 M
|
-$73.54 M
|
-$48.19 M
|
$7.00 K
|
-$9.93 M
|
-$1.83 M
|
-$5.00 K
|
$5.00 K
|
-$527.00 K
|
$174.00 K
|
| Income Before Tax |
-$35.75 M
|
-$116.54 M
|
-$87.97 M
|
-$36.86 M
|
-$23.22 M
|
-$16.01 M
|
-$14.07 M
|
-$13.12 M
|
-$37.96 M
|
-$45.09 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$431.00 K
|
$0.00
|
$0.00
|
-$2.35 M
|
-$404.00 K
|
$0.00
|
-$5.00 K
|
$0.00
|
$136.00 K
|
$0.00
|
| Net Income |
-$36.18 M
|
-$116.54 M
|
-$87.97 M
|
-$34.51 M
|
-$22.81 M
|
-$16.01 M
|
-$14.07 M
|
-$13.12 M
|
-$37.96 M
|
-$45.09 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.75 |
-0.0016 |
-6.13 |
-2.33 |
-15.72 |
-27.27 |
-28.11 |
-50.47 |
-1785.21 |
-324.85 |
| EPS Diluted |
-0.75 |
-1.64 |
-6.13 |
-2.33 |
-15.72 |
-27.27 |
-28.11 |
-50.47 |
-1785.21 |
-324.85 |
| Weighted Average Shares Out |
$48.54 M
|
$24.62 M
|
$14.29 M
|
$14.82 M
|
$1.45 M
|
$655.53 K
|
$500.30 K
|
$259.87 K
|
$21.26 K
|
$138.79 K
|
| Weighted Average Shares Out Diluted |
$48.54 M
|
$24.62 M
|
$14.29 M
|
$14.82 M
|
$1.45 M
|
$655.53 K
|
$500.30 K
|
$259.87 K
|
$21.26 K
|
$138.79 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
